Evercore ISI Group Initiates Coverage On Damora Therapeutics with Outperform Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Positive 85.2%

Neg 0% Neu 0% Pos 85.2%

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Outperform rating and announces Price Target of $46.